NEW YORK (GenomeWeb News) – CovalX and Bruker's Daltonics division today announced an agreement to combine their technologies to support research into protein interactions and macromolecular characterization.

The deal will provide customers access to CovalX's High-Mass systems with Bruker Daltonics' MALDI mass spectrometers, a combination of technologies that the two firms said will result in "significantly improved detection capabilities in the 150-2,000 kDa range."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.